Wet age-related macular degeneration (wAMD)
Showing 1 - 25 of >10,000
s in Wet Age-related Macular Degeneration Which Have Never
Active, not recruiting
- Wet Age-related Macular Degeneration
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, Argentina
- +16 more
Jan 16, 2023
Wet Age-related Macular Degeneration Trial (Ranibizumab, SCT510A)
Not yet recruiting
- Wet Age-related Macular Degeneration
- (no location specified)
Jul 28, 2022
Wet Age-related Macular Degeneration Trial in Beijing (Aflibercept)
Completed
- Wet Age-related Macular Degeneration
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 19, 2022
Wet Age-related Macular Degeneration Trial in United States (Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)
Recruiting
- Wet Age-related Macular Degeneration
- Eyp-1901
- Aflibercept 2Mg/0.05Ml Inj,Oph
-
Melbourne, Florida
- +4 more
Aug 18, 2022
Age Related Macular Degeneration Trial in Xuzhou (recombinant anti-vascular endothelial growth factor (VEGF) humanized mAb
Recruiting
- Age Related Macular Degeneration
- recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
-
Xuzhou, Jiangsu, ChinaXuZhou Central Hospital
Feb 7, 2022
Neovascular (Wet) Age-related Macular Degeneration (nAMD) Trial (EXG102-031)
Not yet recruiting
- Neovascular (Wet) Age-related Macular Degeneration (nAMD)
- EXG102-031
- (no location specified)
Jun 13, 2023
Wet Macular Degeneration Trial in Germany, United Kingdom, United States (BI 836880)
Suspended
- Wet Macular Degeneration
- BI 836880
-
Palo Alto, California
- +13 more
Aug 24, 2022
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema Trial in United States (KSI-301)
Terminated
- Wet Age-related Macular Degeneration
- +2 more
-
Phoenix, Arizona
- +10 more
Nov 1, 2022
Use of Aflibercept Injections Into Eye for Treatment of Eye
Recruiting
- Retinal Disease
- Aflibercept (BAY86-5321, Eylea)
-
Multiple Locations, MexicoMany locations
Aug 22, 2022
Wet Age-related Macular Degeneration Trial in Bern (Aflibercept, Brolucizumab, early treat and extend (T&E))
Enrolling by invitation
- Wet Age-related Macular Degeneration
- Aflibercept
- +2 more
-
Bern, SwitzerlandBerner Augenklinik am Lindenhofspital
May 13, 2022
Neovascular Age-related Macular Degeneration Trial in Italy (Brolucizumab)
Recruiting
- Neovascular Age-related Macular Degeneration
-
Ancona, AN, Italy
- +18 more
Aug 10, 2022
Wet Age-related Macular Degeneration Trial in Puerto Rico, United States (KSI-301, Aflibercept, Sham Procedure)
Active, not recruiting
- Wet Age-related Macular Degeneration
- KSI-301
- +2 more
-
Phoenix, Arizona
- +65 more
Jun 2, 2022
Wet Age-related Macular Degeneration Trial in Hungary (ALK4290)
Completed
- Wet Age-related Macular Degeneration
-
Budapest, Hungary
- +4 more
Nov 30, 2020
Age-Related Macular Degeneration Trial in Toronto (NG101 AAV gene therapy)
Not yet recruiting
- Age-Related Macular Degeneration
- NG101 AAV gene therapy
-
Toronto, Ontario, CanadaVitreous Retina Macula Specialists of Toronto
Aug 2, 2023
Wet Age-related Macular Degeneration Trial in Hungary (ALK4290)
Completed
- Wet Age-related Macular Degeneration
-
Budapest, Hungary
- +4 more
Nov 23, 2020
Wet Age-related Macular Degeneration Trial (SCT510A)
Not yet recruiting
- Wet Age-related Macular Degeneration
- (no location specified)
Sep 21, 2020
Age-related Wet Macular Degeneration Trial in United States (CG-P5 peptide, Placebo, Aflibercept Injection [Eylea])
Not yet recruiting
- Age-related Wet Macular Degeneration
- CG-P5 peptide
- +2 more
-
Augusta, Georgia
- +3 more
Nov 13, 2023
Wet Age-related Macular Degeneration Trial in Beijing (Drug 601)
Unknown status
- Wet Age-related Macular Degeneration
- Drug 601
-
Beijing, ChinaBeiJing Hospital
Jul 8, 2020
RGX-314 Administered in the Suprachoroidal Space for nAMD
Enrolling by invitation
- Neovascular Age-Related Macular Degeneration (nAMD)
- +5 more
- No intervention.
-
Phoenix, Arizona
- +14 more
Jan 14, 2022
AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))
Recruiting
- AMD
- +5 more
- RGX-314 Dose 1
- +2 more
-
Encino, California
- +16 more
Jun 2, 2022
Intestinal Microbiome in Wet Age-related Macular Degeneration
Recruiting
- Age-Related Macular Degeneration
- Sample examination
-
Ioánnina, Epirus, Greece
- +1 more
Feb 23, 2023
Age Related Macular Degeneration Trial in China (HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized
Recruiting
- Age Related Macular Degeneration
- HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
- Lucentis
-
Bengbu, Anhui, China
- +40 more
Apr 27, 2022
Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- SKG0106
-
Katy, Texas
- +1 more
Aug 15, 2023